SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-159128
Filing Date
2021-05-12
Accepted
2021-05-12 16:31:35
Documents
16
Period of Report
2021-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d541436d8k.htm   iXBRL 8-K 31678
2 EX-10.1 d541436dex101.htm EX-10.1 152580
3 EX-99.1 d541436dex991.htm EX-99.1 8550
4 EX-99.2 d541436dex992.htm EX-99.2 22603
8 GRAPHIC g541436dsp2541436.jpg GRAPHIC 3507
  Complete submission text file 0001193125-21-159128.txt   401221

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mgta-20210512.xsd EX-101.SCH 3073
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20210512_lab.xml EX-101.LAB 18123
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20210512_pre.xml EX-101.PRE 11407
9 EXTRACTED XBRL INSTANCE DOCUMENT d541436d8k_htm.xml XML 3347
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 21915583
SIC: 2834 Pharmaceutical Preparations